Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)
Clinical trial NCT05422781 · COMPLETED
Trial details
- NCT number
- NCT05422781
- Sponsor
- Immunomic Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-13
- Primary completion
- 2023-06-27
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.